• Featured Product
  • KD/KO Validated

STK17B Polyclonal antibody

STK17B Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IHC, ELISA

Conjugate

Unconjugated

Cat no : 26600-1-AP

Synonyms

DRAK2, serine/threonine kinase 17b, STK17B



Tested Applications

Positive WB detected inA375 cells, HepG2 cells, K-562 cells
Positive IHC detected inhuman lymphoma tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:100-1:400
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

The immunogen of 26600-1-AP is STK17B Fusion Protein expressed in E. coli.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen STK17B fusion protein Ag24389
Full Name serine/threonine kinase 17b
Calculated Molecular Weight 372 aa, 42 kDa
Observed Molecular Weight 42 kDa
GenBank Accession NumberBC016040
Gene Symbol STK17B
Gene ID (NCBI) 9262
RRIDAB_2880570
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Serine/threonine kinase 17B (STK17B), also named as DRAK2, whose gene is located on chromosome 2 (2q32.3), was first reported by Sanjo et al. in 1998 (PMID: 9786912). STK17B has been identified as a promising therapeutic target for type 1 diabetes, multiple sclerosis, and graft rejection. There are also some reports demonstrated that STK17B was related to apoptosis in various cell types, such as islet β-cells and acute myeloid leukemia cells. Some researches revealed that STK17B was deregulated in some cancers and have important role in cancer progression (PMID: 29445189). It has an indispensable role in NAFLD/NASH and offer a potential therapeutic arget for this disease (PMID: 34614409).

Protocols

Product Specific Protocols
WB protocol for STK17B antibody 26600-1-APDownload protocol
IHC protocol for STK17B antibody 26600-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIHC

Cell Metab

DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.

Authors - Yufeng Li
  • KO Validated